Skip to content

BioMarin Pharmaceuticals BMRN Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$520.42M+61.5%$657.24M+156%$523.88M+155%
$73.9M-18.9%$79.56M-17.5%$82.73M-17.0%$83.25M-21.7%$91.15M-13.5%
$187.17M+3.4%$181.41M-10.0%$186.42M-8.8%$180.64M-13.7%$181.02M-14.5%
$874.25M+24.8%$827.99M+44.5%$913.98M+120%$766.77M+133%$700.26M+150%
$107.19M+40.9%$103.04M+20.6%$81.85M-13.7%$71.86M-26.7%$76.09M-22.6%
$339.52M-$414.24M-$295.39M
$806.4M-$45.55M
$2.02B+571%$368.84M+96.5%$574.66M$241.67M$301.81M
$767.06M+22.9%$724.96M+48.7%$832.13M$694.91M$624.18M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does BioMarin Pharmaceuticals generate?
BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
What is BioMarin Pharmaceuticals's free cash flow?
After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
Where does BioMarin Pharmaceuticals's cash flow data come from?
Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.